BTK and diffuse large B-cell lymphoma: Whole exome sequencing identified somatic mutations in MYD88 wild-type WM patients that are predicted to trigger NFKB (TBL1XR1, PTPN13, MALT1, BCL10, NFKB1, NFKB2, NFKBIB, NFKBIZ, and UDRL1F), impart epigenomic dysregulation (KMT2D, KMT2C, KDM6A), or impair DNA damage repair (TP53, ATM, and TRRAP).10▪ Predicted NFKB activating mutations were downstream of BTK, and many overlapped with somatic mutations found in DLBCL.10▪